Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine. | Despite ...

Hot on the heels of a $150 million fundraise, Atsena Therapeutics is back with early-stage data for the company’s eye disease ...

Recent lawsuits from nonprofits, state attorneys general, unions and local governments say the reorganizations and reductions ...

The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...

Pfizer-backed CellCentric has secured $120 million in series C funds as the British biotech prepares to take its multiple ...

Boehringer Ingelheim’s long-awaited phase 3 lung disease data received a muted reception from analysts who labelled ...

Armata Pharmaceuticals has posted early validation of its phage platform. The phase 1b/2a trial linked a bacteriophage ...

| Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce ...

Applied Therapeutics’ rare disease drug has failed another late-stage clinical trial, adding to the woes of a candidate that ...

Apnimed’s star sleep apnea asset has hit the latest landmark on its march down victory road. | Apnimed’s star sleep apnea ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

After a patient died following a high dose of Neurogene’s Rett syndrome gene therapy candidate, the biotech is sharing ...